JJ
REGN icon

JDC-JSC’s Regeneron Pharmaceuticals REGN Stock Holding History

JDC-JSC’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$672K Buy
1,200
+200
+20% +$121K 3.23% 11
2020
Q2 		$624K Buy
+1,000
New +$568K 1.02% 12

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JDC-JSC's REGN Position: Q3 2020 in Review

JDC-JSC increased its Regeneron Pharmaceuticals (REGN) stake by 20% in Q3 2020, buying an estimated $121K and bringing the position to 1,200 shares worth $672K. The position accounts for 3.23% of the portfolio, ranked #11.

JDC-JSC first reported a position in REGN in Q2 2020 and has held it in 2 quarters since. 908 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

  • JDC-JSC held 1,200 shares of Regeneron Pharmaceuticals worth $672K as of Q3 2020.
  • JDC-JSC bought 200 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $121K.
  • Regeneron Pharmaceuticals made up 3.23% of JDC-JSC's portfolio in Q3 2020, its #11 holding.
  • JDC-JSC first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 2 quarters since.
  • 908 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on JDC-JSC's 13F filing for Q3 2020, filed 3 Nov 2020.